dupilumab
sanofi,regeneron
['dupixent', 'dupilumab', 'derm', 'regeneron', 'sanofi']
study in hard-to-treat hand-foot #atopicdermatitis shows that and s il-4 inhibitor dupixent still has more to give in the common skin disorder #aad23 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate